B. Riley lowered the firm’s price target on NGM Biopharmaceuticals to $7 from $8 and keeps a Buy rating on the shares post the Q4 results. The analyst remains "encouraged" by NGM’s shift to a focus on pursuing novel myeloid biology targets within oncology.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NGM:
